We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Large Stroke Study Confirms Value of Speed and tPA

By HospiMedica staff writers
Posted on 18 Mar 2004
A study of more than 2,700 stroke patients in six controlled clinical trials has confirmed the benefits of getting patients to the hospital quickly and giving them speedy thrombolytic treatment with tissue plasminogen activator (tPA). More...
The results were reported in the March 6, 2004, issue of The Lancet.

Although doctors have known since a breakthrough study in 1995 that early thrombolytic therapy can improve a stroke patient's chance of full recovery, only about 2-5% of all U.S. eligible acute stroke patients are treated with tPA. In the study, those patients who were treated within 90 minutes of the onset of symptoms showed the most improvement. While the study suggests that tPA given up to four hours after symptoms appear may be beneficial, the authors note that the effect lessens as time goes on, and almost no benefit can be expected when tPA is given after six hours.

The pooled results of three other stroke trials also appear in the same issue of the Lancet. These results suggest that the beneficial effect of tPA may extend beyond three hours (from 181-270 minutes), and one trial failed to show any efficacy when tPA was given in the four-to-five-hour window.

"Once again we learn that time is brain,” said John R. Marler, M.D., one of the study authors and associate director for clinical trials at the U.S. National Institute of Neurological Disorders and Stroke (NINDS; Bethesda, MD, USA; www.ninds.nih.gov). "Although rapid stroke treatment presents a great challenge to physicians and may require substantial change in many healthcare systems, we now have stronger evidence that rapid early treatment offers the best chance of recovery for acute ischemic stroke patients.”




Related Links:
NINDS

Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Adjustable Mobile Barrier
M-458
Ureteral Dilatation Balloon
Dornier Equinox
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.